Tag: Bristol-Myers Squibb (BMY)

Compugen: A Stock To Keep

Compugen Compugen (CGEN) cancer immunotherapy’s predictive target computational discovery platforms enabled it to identify two checkpoint proteins, PVRIG and TIGIT, when nobody else could. Compugen’s technological capability has also enabled it to create therapeutic inhibitors of its two discovered targets. The discoveries happened to be important in improving cancer immunotherapy. The lead therapeutic candidate, COM701 . . . This content is for paid subscribers. Please …

Compugen: Predictive Computational Discovery Technology

Compugen IND Application for Triple Combination Study Cleared by the US FDA The U.S. Food and Drug Administration has cleared Compugen’s (CGEN) investigational new drug (IND) application for its Phase 1/2 study evaluating the triple combination of COM701, Compugen’s first-in-class anti-PVRIG antibody, OPDIVO® (nivolumab) -- Bristol Myers . . . This content is for paid subscribers. Please click here to subscribe or here to log in.

Encouraging Results From Nektar’s Product BEMPEG: NKTR-214 In Combination with the Checkpoint Inhibitor Nivolumab

Nektar Therapeutics Nektar Therapeutics (NKTR) announced the publication of Phase 1 clinical data for its immuno-oncology candidate, bempegaldesleukin (BEMPEG: NKTR-214) + nivolumab, in Cancer Discovery -  a journal of the American Association for Cancer Research. Previously published Phase 1 data in Cancer Discovery informed that BEMPEG administered as monotherapy . . . This content is for paid subscribers. Please click here to subscribe or here to log in.

The Time Has Come for This Small Biotech Firm to Grow and Thrive

CytomX Therapeutics CytomX (CTMX) is a clinical-stage oncology-focused biopharmaceutical company developing a novel class of investigational antibody therapeutics based on the firm’s Probody® technology platform for cancer treatments. CytomX’s Probody therapeutics remain inactive until they are activated by proteases in the tumor microenvironment.   Why This is Important By remaining inactive until activated by the cancers’ microenvironment’s proteases, the Probody therapeutics minimizes the active drug’s toxicity …
Prohost Letter #439

Prohost Letter #439

Prohost Letter #439 The Coronavirus Outbreak - COVID-19 The news announced that the coronavirus (now known as COVID-19) outbreak would affect not only people’s health and survival but the world’s economy, Wall Street’s performance, and especially the international giant industrial firms that are committed to China. British AstraZeneca (AZN

Compugen

Time to Remember Compugen The time has ripened for our readers and biotech investors to remember what we posted in the past years about Compugen (CGEN). The importance of the reminder is that the firm has taken a long time to bring its target discoveries and its targeted treatments into clinical trials whose preliminary results have demonstrated promise. Compugen
Nektar Is Still a Favorite

Nektar Is Still a Favorite

Nektar in the NEWS The FDA's Anesthetic and Analgesic Advisory Committee (AADPAC) and Drug Safety and Risk Management Advisory Committee (DSaRM) unanimously voted no regarding the approval of Nektar Pharmaceuticals’ (NKTR) New Drug Application (NDA) for its opioid product oxycodegol (formerly NKTR-181). In a short
The Beginning of a Nektar Outperformance?

The Beginning of a Nektar Outperformance?

Nektar Therapeutics and Bristol-Myers Squibb Agreement Nektar Therapeutics (NKTR) and Bristol-Myers Squibb (BMY) announced their agreement for a new joint development plan aimed at advancing the combination of Nektar’s bempegaldesleukin (bempeg) + Bristol-Myers’ Opdivo (nivolumab) into multiple new registrational trials. The decision is based on a revision of the strategic collaboration agreement. It includes a new plan where both firms will expand the active clinical development …
Nektar at the 61st American Society of Hematology (ASH) Meeting

Nektar at the 61st American Society of Hematology (ASH) Meeting

Nektar Therapeutics Presents NKTR-255 at ASH Nektar Therapeutics’ (NKTR) IL-15 agonist investigational candidate NKTR-255 presentations at the 61st American Society of Hematology (ASH) Annual Meeting & Exposition have been promising. Positive data presented from Fred Hutchinson Cancer Research Center preclinical studies conducted in collaboration with researchers from the Dana-Farber Cancer Institute and more. NKTR-255 is currently . . . This content is for paid subscribers. …
What A Week For Biotechnology

What A Week For Biotechnology

The Week in Review #47 What A Week For Biotechnology Synopsis In this “Week in Review” there is no complicated scientific and clinical information, leaving the details to the articles that we usually post on the Prohost website. Most of the Prohost picked firms’ Q3 financial results have beaten expectations. Three firms have reached the Prohost 2019 targets, and more firms have outperformed, with some …
News from NKTR, BMY and MRK. See Also: Biotechs’ Bizarre Performances in Early Trading Hours Today

News from NKTR, BMY and MRK. See Also: Biotechs’ Bizarre Performances in Early Trading Hours Today

News from Nektar Nektar Therapeutics (NKTR) announced that new data from patients with metastatic triple-negative breast cancer, who were enrolled in the PIVOT-02 study, will be presented at the upcoming 5th CRI-CIMT-EATI-AACR Cancer Immunotherapy Conference being held from September 25 to September 28, 2019 in Paris, France. The PIVOT-02 study is evaluating NKTR-214 . . . This content is for paid subscribers. Please click here to subscribe …
Amgen to Acquire Celgene’s Product Otezla at $13.4 Billion

Amgen to Acquire Celgene’s Product Otezla at $13.4 Billion

Amgen Agreement with Celgene for Otezla® In the News Amgen (AMGN) entered into an agreement with Celgene (CELG) to acquire worldwide rights to Otezla® (apremilast), the only oral, non-biologic treatment for psoriasis and psoriatic arthritis, and certain related assets and liabilities for $13.4 billion in cash. Amgen cited the benefits of this agreement as follows: A strong fit with Amgen’s long-standing expertise in inflammation and …
Nektar’s Story Has Nothing to Do with the Efficacy Or the Value of NKTR-214

Nektar’s Story Has Nothing to Do with the Efficacy Or the Value of NKTR-214

Nektar Therapeutics Story Everything was going well with Nektar Therapeutics (NKTR) stock during the Conference call regarding the firm’s Q2 financial results. (See the firm's press release under our Impacting News column). Following the Conference call the company unveiled that some of the patients treated in . . . This content is for paid subscribers. Please click here to subscribe or here to log in.
Gilead Sciences Activities Are Exceeding Its All Time High. Celgene Demonstrates How Valuable It Could be for Bristol-Myers Squibb.

Gilead Sciences Activities Are Exceeding Its All Time High. Celgene Demonstrates How Valuable It Could be for Bristol-Myers Squibb.

Gilead Sciences Activities There is no doubt that Gilead Sciences (GILD) is doing whatever it takes to expand, improve and upgrade its pipeline products. For the last couple of months, each and every week, we heard news about collaborations with some companies and investment in others as well as licensing products from large, medium-sized and small firms. In less than ten . . . This content is for …
Nektar Product NKTR-358 Shows Promise in Autoimmune and Chronic Inflammatory Conditions

Nektar Product NKTR-358 Shows Promise in Autoimmune and Chronic Inflammatory Conditions

Nektar Announced Results for NKTR-358  During an oral session at the Annual European Congress of Rheumatology (EULAR) 2019, in Madrid, Nektar Therapeutics (NKTR) announced results of the first-in-human Phase 1a study evaluating single-ascending doses of NKTR-358 for the treatment of autoimmune and other chronic inflammatory conditions.  The . . . This content is for paid subscribers. Please click here to subscribe or here to log in.
Why CRISPR Therapeutics’ stock gained around $8 today

Why CRISPR Therapeutics’ stock gained around $8 today

CRISPR Therapeutics' (CRSP) stock added around $8 today while reporting financial results for the fourth quarter and full year ended December 31, 2018. Here is what Samarth Kulkarni, Ph.D., Chief Executive Officer of CRISPR Therapeutics, has stated,“This past year was truly transformational for CRISPR Therapeutics as we achieved milestones across our key programs in β-thalassemia, sickle cell disease and immuno-oncology. We’re pleased with the progress we’ve made in …